TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 14, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 18,320 shares of its common stock and an aggregate of 12,068 restricted stock units to 8 employees, each as a material inducement for each employee's entry into employment with TransMedics. The g
Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
On May 7, 2024, Edward Basile, Director at TransMedics Group Inc (NASDAQ:TMDX), sold 7,157 shares of the company.